The Priority Review

Clinical trials Brief

Antengene announces first patient dosed in Phase I ATTRACT study of ATG-201

The company announced dosing began on Nov. 5, 2026 in China. The study is being conducted in China and Australia, and ATG-201 has received Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with the Therapeutic Goods Administration.

Primary source

Company press release (PR Newswire), November 5, 2026

Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases

Read the source: Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases prnewswire.com

Machine-summarized from the source above; not independently reported. How we use automation